Abstract Background. Cabergoline is a long-acting dopamine-agonist drug that suppresses prolactin secretion and restores gonadal function in women with hyperprolactinemic amenorrhea. We designed a study to compare its safety and efficacy with those of bromocriptine, which has been the standard therapy.
D OPAMINE-AGONIST drugs are the treatment of choice for most patients with hyperprolactinemia.',' Bromocriptine has been the reference compound and effectively suppresses prolactin secretion, restores gonadal function, and shrinks pro lac ti no ma^.^ It has a number of side effects, however, including nausea, dizziness, and headache, that limit the dose and may even necessitate the withdrawal of treatment.4-6 Furthermore, its half-life is short so that it must be given two or three times daily.
Cabergoline is a new, selective, potent, and longlasting dopamine agonist that inhibits prolactin secretion in both normal subjects and those with hyperprolactinemia, with a duration of action of up to 21 days after single oral doses of 0.3 to 1.0 mg.7-9 I n a recent multicenter study in women with hyperprolactinemia, cabergoline in doses of 0.125 to 1.0 mg twice weekly for four weeks decreased prolactin secretion in a dose-dependent fashion, and 95 percent of those receiving 1.0 mg twice weekly had normal serum prolactin concentration^.'^ I n short-term studies83l0 and in the first reports of long-term treatment,"-'3 the drug was well tolerated, and its side effects were similar to those reported with bromocriptine. We carried out this randomized, parallel-group, partially double-blind study in order to compare the Results. Stable normoprolactinemia was achieved in 186 of the 223 women treated with cabergoline (83 percent) and 138 of the 236 women treated with bromocriptine (59 percent, P<0.001). Seventy-two percent of the women treated with cabergoline and 52 percent of4hose treated with bromocriptine had ovulatory cycles or became pregnant during treatment (P<0.001). Amenorrhea persisted in 7 percent of the cabergoline-treated women and 16 percent of the bromocriptine-treated women. Adverse effects were recorded in 68 percent of the women taking cabergoline and 78 percent of those taking bromocriptine (P = 0.03); 3 percent discontinued taking cabergoline, and 12 percent stopped taking bromocriptine (P<0.001) because of drug intolerance. Gastrointestinal symptoms were significantly less frequent, less severe, and shorterlived in the women treated with cabergoline.
Conclusions. Cabergoline is more effective and better tolerated than bromocriptine in women with hyperprolactinemic amenorrhea. (N Engl J Med 1994; 331:904-9.) effectiveness and tolerability of bromocriptine and cabergoline in women with hyperprolactinkmia.
Study Design
The study was a randomized, multicenter 24-week trial Bibparing cabergoline (0.5 to 1 .(! mg twice weekly) with bromocriptine (2.5 to 5.0 mg twice daily) in the treatment of women with hyperprolactinemic amenorrhea. T h e women were recruited from 67 gynecological and endocrirlologic centers in Europe and Argentina. The study was approved by the institutional review board at each center, and the women gave their informed consent, either written or oral and witnessed. Treatment was given under double-blind conditions for the first eight weeks and subsequently continued on an openlabel basis. The reasons for this combined design included the different dose schedules for the two drugs, which, if double-blind conditions were continued throughout the study, would have imposed a twice-daily administration schedule on the women assigned to receive cabergoline. In addition, side effects from ergot derivatives occur during the first few weeks of treatment and decline progressively thereafter. Hence, double-blind administration during the first part of the study would ensure unbiased assessment of side effects when most would be anticipated to occur. Adequate comparison of the effectiveness of the two drugs under open conditions was ensured by the objective criteria used for this purpose.
Selection of Patients
We studied 459 women 16 to 45 years of age who had had amenorrhea for at least three months and serum prolactin concentrations at least twice the upper limit of normal values for each center (Table I) on two occasions at least four weeks after the discontinuation of any previous therapy: serum prolactin concentrations of this magnitude were obtained in all but 9 of the 313 women who had been previously treated. Women who had been treated previously with either drug were not excluded unless they had had to discontinue treatment because of adverse events or had not had a 50 percent reduction in serum prolactin concentrations. Additional criteria for exclusion were the presence of a pituitary macroadenoma, any disorder that could prevent normal menstruation after the restoration of normoprolactinemia, hyperprolactinemia related to polycystic ovary disease, thyroid or adrenal disorders, renal or hepatic disease, 
Criteria of Efficacy
The efficacy of treatment was assessed with clinical criteria (the occurrence of menses and ovulation) and biochemical measurements (serum prolactin concentrations). Complete clinical success was defined as the occurrence of at least two consecutive menses with biochemical evidence of ovulation 'Plus-minus values are means ?SD. BRC denotes bromocriptine, and CAB cabergoiine tNo detectable adenoma on cornpuled tomography or magnetlc resonance imag~ng. tMacroprolacllnomas; one woman dropped out before starfing treatment. the other had a history oEa macroadenoma that had shrunk to 6 mm in diameler after dopamine-agonzst therapy.
BMacroprolactinoma was treated surgically, with no residual hlmor tissue visible on computed tomography.
(ICraniopharyngioma was treated surgically, with no evidence of residual tissue on computed tomography.
.. .
and a history of aller<gy to ergot derivatives. All women had normal plasma concentrations of luteinizing hormone, follicle-stimulating hormone, and progesterone; normal tests of renal and hepatic function; normal complete blood counts; normal electrocardiograms; and negative pregnancy tests. All women underwent computed tomography or magnetic resonance imaging of the pituitary region (unless these tests had been performed within the preceding 12 months).
on at least one occasion (plasma progesterone concentration above 7.9 ng per milliliter [25 nmol per liter] in samples obtained during the midluteal phase or above 3.2 ng per milliliter [I0 nmol per liter] in samples not taken during the midluteal phase) or pregnancy. Partial clinical success was defined as the occurrence of two menstrual cycles without evidence of ovulation or a single ovulatory cycle. For women who did not require an adjustment in the dose, complete biochemical success was defined as a serum prolactin value within the normal range after week 6. For those whose dose was changed at week 8 or 16. biochemical success was defined as a normal serum prolactin value from week 12 or 20,
Treatment
Each woman was centrally assigned to feceive one of the study drugs in a double-blind fashion, according to computer-generated randomization lists that were stratified on the basis of country and previous therapy with either drug. During the first eight weeks the women took one tablet and one capsule (containing active drug or placebo) twice daily, with their morning and evening meals. The women assigned to the cabergoline group initially received 0.25 mg of active drug on days 1 and 5 (evening doses), and the dose was increased to 0.5 mg on the same days during weeks 2 to 8. Bromo- criptine was started at a daily dose of 1.25 mg (evening dose) for three days, and the dose was increased to 2.5 mg daily for the next four days and subsequently to 2.5 mg twice daily during weeks 2 to 8. During the open-label period, dose adjustments were made, if necessary, at the end of week 8 or 16 (or both) on the basis of the serum prolactin values at the previous visit (weeks 6 and 14). The dose of bromocriptine was increased from 2.5 mg twice daily to 2.5 mg three times daily and subsequently to 5 mg twice daily; the dose of cabergoline was increased to 0.5 mg three times weekly (days 1, 3, and 5 ) and then to 1 mg twice weekly.
respectively Partial success was defined as a serum prolact~n value above the normal range at these times, but less than 50 percent of the base-llne value. Biochemical failure was defined as serum prolactin concentrations remaining above 50 percent of the base-line values.
f Statistical Anafysls
The null hypothesis of the suprriority by 10 percent grdrmbre of bromocriptine was tested against an alternative hypothesis of a difference of less than 10 percent in favor of bromocriptine," which was considered to be clinically irrelevant. The clinical and biochemical success rates in the two groups were compared with Blackwelder's modified z statistics.15 A complementary analysis of success rates used a logistic model including stratum (previous treatment with test drugs), treatment, and their interaction as explanatory variable^.'^," The intention-to-treat approach was used in evaluating the results. The results of analysis based only on women who could be fully evaluated (i.e., those fulfilling the eligibility criteria and completing the entire treatment period with correct dose adjustments) were similar to those of the intention-to-treat analysis. The effects of the treatments on blood pressure, pulse, and
Monitoring
Serum prolactin was measured at base line and 2, 4, 6, 8, 12, 14, 16, 20 , and 24 weeks after the initiation of therapy. The duration of each episode of vaginal bleeding was recorded, but only episodes lasting at least two days were considered to be menses. When menses were restored, plasma progesterone was measured during the presumed luteal phase as an indicator of ovulation. If necessary, extra visits were arranged (on day 2 1 of the cycle) for this purpose.
Serum prolactin and plasma progesterone were measured at each center soon after the samples were obtained by different immunologic methods with the use of international standards.
At each visit the women were asked about side effects, which were classified as mild (awareness of symptoms, but easily tolerated), moderate (enough discomfort to interfere with usual activities), or hematologic and biochemical values were evaliated by descriptive statistics that included two-tailed t-tests, the median sign-rank test, and the Stuart Maxwell test. Adverse events were compared with the chi-square test; in addition, the cumulative risk and the instantaneous probability (hazard) of adverse events were estimated by life- The women in each treatment group were comparable in terms of age, height, weight, base-line serum prolactin concentration, duration of amenorrhea, and diagnosis ( Table 1 ) . The median periods without treatment were five months in the bromocriptine group and six months in the cabergoline group. At base line 434 of the 459 women had amenorrhea; 14 women in the bromocriptine group and 1 1 in the cabergoline group reported vaginal bleeding in the preceding three months.
In the bromocriptine group, 214 of the 236 women (91 percent) completed eight weeks of treatment and 169 (72 percent) completed the entire treatment period. The corresponding figures for the 223 women in the cabergoline group were 21 1 (95 percent) and 186 (83 percent). Seven women did not start treatment (five in the bromocriptine group and two in the cabergoline group). The final drug doses are shown in Figure 1 . Therapy was discontinued before the end of the study in 67 women in the bromocriptine group and 37 women in the cabergoline group for the following reasons: pregnancy (12 in the bromocriptine group and 18 in the cabergoline group), drug intolerance (27 and 7, respectively), loss to follow-up (4 in each group), poor compliance with the visit schedule (6 in the bromocriptine group), and miscellaneous causes (18 in the bromocriptine group and 8 in the cabergoline group). Compliance was good in both treatment groups: none of the women in the cabergoline group and only six women in the bromocriptine group took less than 80 percent of the prescribed dose. During the open-label period, compliance with the twiceweekly schedule adopted for cabergoline was better than that with the twice-daily bromocriptine regimen tP<0.001 for the companson with the bromocnptine group. $Th~s category includes women who dropped out of the study (47 in the bromccriptine group and 13 in the cabergoline group) and women who did not have plasma progesvrone measurements (I l in the bromocriptine group and 19 in the cabergoline group).
§This category includcs women who dropped out of the study (42 in the bromocriptine group and 13 in the cabergoline group) and women who had only one measurement of serum prolactin while receiving the final dose of drug (9 women in the brommnptine group and 3 in the cabergoline group).
(18 percent of women missed a t least one dose of cabergoline, and 44 percent of women missed a dose of bromocriptine). Among the women who completed the study, menses resumed in 87 percent of those taking bromocriptine and 96 percent of those taking cabergoline. When we excluded the women who became pregnant without resuming menses (3 women treated with bromocriptine and 4 treated with cabergoline) and those who were randomized but never started treatment (5 treated with bromocriptine and 2 with cabergoline), amenorrhea persisted in 37 of those taking bromocriptine (16 percent) and in 16 of the women treated with cabergoline (7 percent).
Clinical Efficacy
Among women whose menses resumed, plasma progesterone was measured at least once in 187 of those in the bromocriptine group (98 percent) and 191 of those in the cabergoline group (95 percent). Of these, 123 in the bromocriptine group (66 percent) and 156 in the cabergoline group (82 percent) had at least one ovulatory cycle. The proportions of women with complete or partial clinical success or failure are shown in Table  2 . The difference in the rates of complete success was 20 percent (95 percent confidence interval, 11 to 28 percent) and clearly indicated the superiority of cabergoline over bromocriptine. Of the 90 women in whom a clinical response could not be determined, most (the "not applicable" category in Table 2 ) dropped out of the study with no proved ovulation, and the remainder did not have plasma progesterone measurements. The effects of cabergoline were superior to those of bromocriptine when the rate of clinical success was analyzed according to base-line serum prolactin values (77 percent vs. 59 percent in women with pretreatment serum prolactin concentrations below 100 p g per liter and 62 percent vs. 39 percent in those with pretreatment serum prolactin concentrations of at least 100 p g per liter). Before therapy, 48 women in the cabergoline group and 45 women in the bromocriptine group had galactorrhea, which disappeared in 90 percent and 78 percent, respectively, usually within eight weeks after the start of treatment.
Sixteen women treated with bromocriptine and 25 treated with cabergoline conceived, but only pregnancies in the latter group were actively monitored. There were 4 elective terminations because of unintended pregnancy, 2 early spontaneous abortions, 16 deliveries (1 cesarean and 15 vaginal), and 1 therapeutic abortion in a woman carrying a n abnormal fetus (the fetus had anomalies of the legs probably related to amniotic bands); two women were lost to follow-up. All infants delivered were normal.
Biochemical Efficacy
The base-line serum prolactin concentrations were similar in the two groups ( Table 1 ). The mean serum prolactin concentrations during the study are shown in Figure 2 . T h e mean serum prolactin concentration fell rapidly during the first two weeks of treatment in both groups. From week 4 onward, it was well within the normal range in the cabergoline group but remained slightly above normal in the bromocriptine group. ~h~r a t e s of complete and partial biochemical success and biochemical failure are shown in Table 2 . The difference in the rate of complete success was 25 percent (95 percent confidence interval, 17 to 33 percent) in favor of caberoline. The serum prolactin re--sponse was not adequately assessed in 67 women (the "not applicable" category in Table 2 ) because they dropped out of the study or because only a single prolactin measurement was made at the final dose.-1n the bromocriptine group, the effective daily dose was 2.5 mg in 1 woman, 5 mg in 124, 7.5 mg in 10, and 10 mg in 3. T h e effective weekly cabergoline doses were 0.5 mg in 3 women, 1 mg in 167, 1.5 mg in 14, and 2 mg in 2.
The differences were more pronounced in favor of cabergoline in women who had not received any previous treatment (Table 2) . Cabergoline also was more effective in women with base-line serum prolactin values of either less than 100 p g per liter or 100 p g per liter or higher and in women with either microprolactinomas or idiopathic hyperprolactinemia. However, in both treatment groups the rate of complete success bergoline group) than in those with pretreatment concentrations of 100 p g per liter or higher (43 percent in the bromocriptine group and 73 percent in the cabergoline group).
Drug Safety
With cabergoline therapy, 68 percent of the women reported adverse events, as compared with 78 percent of those taking bromocriptine ( P = 0.03); during the double-blind period, the corresponding values were 63 and 71 percent, respectively ( P = 0.07). The cumulative risk of adverse events during cabergoline treatment was significantly lower than during bromocriptine treatment (odds ratio, 0.6; 95 percent confidence interval, 0.4 to 1.0). I n two thirds of the women who had adverse events, the events occurred within two weeks after therapy was begun; however, 15 to 20 percent of the women in each group had persistent or recurrent early symptoms or had new symptoms in subsequent weeks (Fig. 3) . Overall, adverse events (Table 3) were less frequent and less severe with cabergoline (14 percent vs. 20 percent, P = 0.06), and only 7 women (3 percent) had to discontinue treatment because of intolerance, as compared with 27 women (12 percent) in the bromocriptine group (Pc0.00 1). Among the women treated with bromocriptine, nausea was significantly more frequent (P<0.001), more severe (occurring in 9 percent, as compared with 1 percent of the women treated with cabergoline; P<0.001), and of longer duration. Also, vomiting was more frequent and severe with bromocriptine than with cabergoline. Severe vomiting was reported by 5 percent of the bromocriptine-treated women but by none of the women receiving cabergoline.
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Test Results
Five women (two in the bromocriptine group and three in the cabergoline group) had transient increases in serum alkaline phosphatase or aminotransferase values (>lo0 percent above the upper limit of nor- ~ mal), four of whom had slightly abnormal results at base line. I n two women (one in each group), the abnormality resolved only after treatment was discontinued. Approximately 50 percent of the women in each group had a drop in blood pressure (median decrease, 10 mm Hg), particularly diastolic pressure, which was symptomatic in only three women in the cabergoline group and four in the bromocriptine group. There were no electrocardiographic changes.
Weeks of Treatment
These results provide clear evidence that cabergoline is more effective than bromocriptine in both normalizing serum prolactin and restoring gonadal function in women with hyperprolactinemic amenorrhea. I n the doses used, cabergoline resulted in stable normoprolactinemia in a significantly higher proportion of women than did bromocriptine. The effective doses were 2.5 mg twice daily for bromocriptine and 0.5 mg twice weekly for cabergoline in approximately 90 percent of the women in whom serum prolactin concen- trations became normal. The effect of cabergoline was also more rapid. As anticipated, the prolactin response was dependent on the pretreatment serum prolactin concentration; women with values below 100 p g per liter more often had normal values during treatment.
Cabergoline was also significantly more effective than bromocriptine in restoring gonadal function. The pregnancy rate cannot be interpreted as a n indicator of clinical efficacy, since all women were advised to avoid conception during the double-blind period; as were those treated with cabergoline during the openlabel period. The observation of only two spontaneous abortions in each group is consistent with the known rate of miscarriage in normal women.
The incidence bf adverse symptoms and the number of women discontinuing treatment because of side effects were lower in the cabergoline group. The higher incidence of symptoms in previously treated women may be explained by their earlier experiences of side effects. The most frequent symptoms, typical of dopamine-agonist drugs, included nausea, headache, dizziness or vertigo, abdominal pain, weakness or fatigue, and constipation. The incidence of these symptoms was similar, except that gastrointestinal problems were less common, less severe, and shorter-lived in women treated with cabergoline. O u r results are similar to those of a previous short-term, placebo-controlled trial using the same doses of cabergoline in 188 womenL0 and of open, uncontrolled studies of longterm
The data concerning the efficacy and tolerability of bromocriptine differ from those of earlier open, uncontrolled studies that showed fewer adverse symptoms and better e f f i~a c y ,~ but are in agreement with those of three recent double-blind. randomized trials comparing bromocriptine with q~i n a~o l i d e .~.~
In two of these s t u d i e~,~.~ the doses of bromocriptine and the duration of treatment were the same as i n our study. , , whereas in the third,5 higher doses of bromocriptine (up to 20 mg daily) were allowed and a once-daily dose was used. I n all, 8 1 women with hyperprolactinemia were studied, of whom 40 were treated with bromocriptine. Normoprolactinemia was achieved in 22 of the 40 (55 percent), and menses resumed in 22 of 28 women (78 percent) with oligomenorrhea or amenorrhea. I n conclusion, cabergoline is highly effective and well tolerated in the majority of women with hyperprolactinemic amenorrhea. It has advantages over bromocriptine in terms of both efficacy and tolerability and therefore is a n important advance in the treatment of hyperprolactinemia. 
